BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 30645846)

  • 1. [TCM Combined Western Medicine Treatment of Advanced NSCLC: a Preliminary Study of mIRNA Expression Profiles].
    Li YB; Lin LZ; Guan JS; Chen CM; Zuo Q; Lin BQ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Sep; 36(9):1076-1081. PubMed ID: 30645846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of microRNA expression profiling in non small cell lung cancer.
    Markou A; Sourvinou I; Vorkas PA; Yousef GM; Lianidou E
    Lung Cancer; 2013 Sep; 81(3):388-396. PubMed ID: 23756108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-small cell lung cancer associated microRNA expression signature: integrated bioinformatics analysis, validation and clinical significance.
    Li C; Yin Y; Liu X; Xi X; Xue W; Qu Y
    Oncotarget; 2017 Apr; 8(15):24564-24578. PubMed ID: 28445945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
    Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
    Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of microRNA (miRNA) expression profiles reveals 11 key biomarkers associated with non-small cell lung cancer.
    Wang K; Chen M; Wu W
    World J Surg Oncol; 2017 Sep; 15(1):175. PubMed ID: 28927412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
    Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
    Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer.
    Zhu XL; Ren LF; Wang HP; Bai ZT; Zhang L; Meng WB; Zhu KX; Ding FH; Miao L; Yan J; Wang YP; Liu YQ; Zhou WC; Li X
    World J Gastroenterol; 2019 Apr; 25(13):1580-1591. PubMed ID: 30983818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis.
    Xue WX; Zhang MY; Rui Li ; Liu X; Yin YH; Qu YQ
    Biomed Res Int; 2020; 2020():9601876. PubMed ID: 32724822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of differential expression profile of miRNA in peripheral blood of patients with lung cancer.
    He Q; Fang Y; Lu F; Pan J; Wang L; Gong W; Fei F; Cui J; Zhong J; Hu R; Liang M; Fang L; Wang H; Yu M; Zhang ZF
    J Clin Lab Anal; 2019 Nov; 33(9):e23003. PubMed ID: 31541491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
    Jin X; Chen Y; Chen H; Fei S; Chen D; Cai X; Liu L; Lin B; Su H; Zhao L; Su M; Pan H; Shen L; Xie D; Xie C
    Clin Cancer Res; 2017 Sep; 23(17):5311-5319. PubMed ID: 28606918
    [No Abstract]   [Full Text] [Related]  

  • 11. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer.
    Tian F; Shen Y; Chen Z; Li R; Lu J; Ge Q
    Gene; 2016 Oct; 591(2):338-43. PubMed ID: 27291819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.
    Kumar S; Sharawat SK; Ali A; Gaur V; Malik PS; Kumar S; Mohan A; Guleria R
    Curr Probl Cancer; 2020 Aug; 44(4):100540. PubMed ID: 32007320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytological effects of honokiol treatment and its potential mechanism of action in non-small cell lung cancer.
    Zhang J; Zhang Y; Shen W; Fu R; Ding Z; Zhen Y; Wan Y
    Biomed Pharmacother; 2019 Sep; 117():109058. PubMed ID: 31176168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients.
    Zhang Y; Zhang Y; Yin Y; Li S
    Pathol Res Pract; 2019 Aug; 215(8):152466. PubMed ID: 31146974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
    Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
    Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis.
    Braza-Boïls A; Salloum-Asfar S; Marí-Alexandre J; Arroyo AB; González-Conejero R; Barceló-Molina M; García-Oms J; Vicente V; Estellés A; Gilabert-Estellés J; Martínez C
    Hum Reprod; 2015 Oct; 30(10):2292-302. PubMed ID: 26307093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma.
    Mataki H; Seki N; Mizuno K; Nohata N; Kamikawaji K; Kumamoto T; Koshizuka K; Goto Y; Inoue H
    Oncotarget; 2016 Nov; 7(44):72084-72098. PubMed ID: 27765924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Role of Circulating Exosomal miR-425-3p for the Response of NSCLC to Platinum-Based Chemotherapy.
    Yuwen D; Ma Y; Wang D; Gao J; Li X; Xue W; Fan M; Xu Q; Shen Y; Shu Y
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):163-173. PubMed ID: 30228154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA Expression Profiling in Clear Cell Renal Cell Carcinoma: Identification and Functional Validation of Key miRNAs.
    He H; Wang L; Zhou W; Zhang Z; Wang L; Xu S; Wang D; Dong J; Tang C; Tang H; Yi X; Ge J
    PLoS One; 2015; 10(5):e0125672. PubMed ID: 25938468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
    Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
    Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.